Our findings establish CHIP, particularly TET2 mutations, as an independent risk factor for worsened CAD outcomes, providing novel insights into its pathophysiological role in inflammation, lipid metabolism, and plaque instability. The gene discussed is TET2; the disease is coronary artery disorder.